Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post ...

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) anticipates delivering non-GAAP operating income profitability in 2025. Alnylam announced full year 2025 combined net product revenue guidance for ...

CAMBRIDGE, Mass., January 30, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for ...

Cambridge, MA-based Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference (RNAi). The company’s ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global ...

Alnylam Pharmaceuticals stock opened at $258.27 on Monday. The company has a market capitalization of $33.31 billion, a P/E ratio of -98.58 and a beta of 0.34. The company has a debt-to-equity ...

For the first time in almost 20 years, Walmart has a new logo. The international retailer describes it as a “a comprehensive brand refresh,” but the online world hasn’t been quite so kind to ...

Alnylam Pharmaceuticals ALNY has outperformed the market over the past 15 years by 7.96% on an annualized basis producing an average annual return of 19.36%. Currently, Alnylam Pharmaceuticals has ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Equities research analysts at Zacks Research upped their Q1 2026 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a ...

Alnylam Pharmaceuticals stock advanced after the company said its preliminary 2024 product revenue rose 34%. The shares rose 8% to $256.87 Monday. They are up 37% over the past 12 months. The ...